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IntroductionRandall B. Griepp, MD, and Eva B. Griepp, MD, Guest EditorsThis supplement reflects the experience and opinions of
a group of experts on the treatment of diseases of the aorta,
presented at the most recent Aortic Symposium in New
York in May 2010. Some of the contributions are structured
as state of the art monographs and others as scientific pa-
pers, as determined by their authors. Most of the contribu-
tors are acknowledged leaders in aortic surgery, but a few
of the papers were chosen from submitted abstracts by the
organizing committee as being of extraordinary interest.
In-depth discussions followed each group of presentations:
these discussions have been edited for clarity. It is the hope
of the editors that what emerges from papers and discus-
sions is an accurate reflection of the state of our current
knowledge of how best to treat aortic disease.
With regard to the ascending aorta, we have learned more
about the natural history of this disease, including the im-
portance of genetics and smooth muscle cell modulation
of aortic structure and function, as well as the possibility
of modifying the natural history of aneurysmal disease by
control of hypertension, beta-adrenergic blockade, and
transforming growth factor beta-2 modulation, coupled
with periodic surveillance with improving imaging modal-
ities. From a therapeutic standpoint, the valve-sparing oper-
ation has come of age, and excellent results are achievable
with a Bentall procedure in those in whom the valve cannot
be fixed.
In procedures involving the arch, cerebral protection con-
tinues to be controversial, but good results—apart from the
problem of atherosclerotic emboli—are possible with sev-
eral methods. The long-term outcome of patients with dis-
ease of the arch is disappointing, however, owing to the
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The Journal of Thoracic and Caaorta. Hybrid techniques show promise in addressing exten-
sive aneurysmal disease.
In the descending and thoracoabdominal aorta, repair
continues to carry a high risk of both death and serious com-
plications, particularly spinal cord injury and renal failure.
Purely endovascular and hybrid approaches appear promis-
ing. A better understanding of what is required for spinal
cord and renal protection during these procedures is gradu-
ally emerging. Given the impact of the extensive disease
burden and the physiologic cost of intervention, there is
emerging consensus in this patient population that compar-
ison of treatment effectiveness from one study to another
would be enhanced by routinely reporting 1-year mortality,
and long-term survival should be compared with age- and
sex-matched controls as a standard mortality ratio.
Acute aortic syndromes other than aortic dissection are
still poorly understood in terms of pathogenesis, natural his-
tory, and appropriate treatment, but a start toward under-
standing them has been made. The role of stent grafting is
still unclear in acute type A dissection and in chronic dissec-
tion, both type A and B. A consensus is emerging regarding
the value of stent grafting in complicated type B dissection
and traumatic aortic tear.
During the 22 years since these symposia began, very
substantial advances have been made in understanding
and treating aortic disease. Significant progress is evident
in the past 2 years, but significant challenges remain. The
editors wish to thank all the contributors to the symposium,
both essayists and discussants, and are pleased and gratified
by the opportunity to collaborate with The American Asso-
ciation for Thoracic Surgery and to publish this supplement
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